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Aim: To compare the molecule levels of plasma miRNA (miR-22, miR-24, miR-92b,
miR-320a and miR-423-5p) in acute decompensated heart failure (ADHF) patients
before and after treatment with the controls who do not have HF.
Method: This study included 47 (mean age: 61.7011.75, 63.8% men) patients
hospitalized in intensive care unit with the diagnosis of ADHF and 30 (mean age:
57.138.32, 46.66% men) healthy population. Peripheric blood was withdrawn from
the patients at admission and after treatment and the miR-22, miR-24, miR-92b, miR
320a and miR-423-5p levels were compared with the control group. Venous blood
was withdrawn from patients two times, ﬁrst at hospitalization and second after
treatment before discharge and only once from the controls and were kept at -80
Celsius. After sample collection was concluded, the levels of miRNA detected from
peripheral blood cells (leukocytes) were calculated using the method PCR, and
comparison between groups and within the group of HF miRNA differences were
expressed as fold change (2 to the power of -DD Ct value was used).
Results: The demographic features and the treatment being received at admission is
listed in Table-1. All patients received parenteral furosemide and 8.5% of them had
inotropic drugs at admission. The basal (decompansated) miR-22 levels were detected
as 2.33 fold lower in the patient group than the control group. After medical treatment
before discharge (compensated) the decrease was 1,23 folds, resulting in closer levels
to the control group. Similar level difference was detected with the miRNA 24. The
miR-92 levels were increased both at admission and at discharge compared with the
controls. The amount of increase was 2.33 fold at admission and 3 folds at discharge.
The differences of the levels of miR-423-5p and 320a were not signiﬁcant (Table-2).
The difference of the miRNA levels were similar between ischemic and non-ischemic
heart failure groups.
Conclusion: 1) Acute decompansated heart failure patients have signiﬁcantly
decreased (>2-fold) miR-22 and 24 levels, after obtaining compensation with medical
treatment, it gets closer to the normal population with treatment. 2) In this group of
patients miRNA-22 and 24 levels can be a useful indicator (biomarker) for the
effectiveness of drug therapy.Table-1. General characteristics of HF and control groups
HF group
(n ¼ 47)
Control group
(n ¼ 30) p value
Age (mean)
Gender (m/f)
BMI
HT
HLP
DM
Drugs
BB
ACEi
MRA
61.70
30 / 17
28.07
21 (%44.7)
35 (%74.5)
29 (%61.7)
39 (%88.6)
26 (%59.1)
13 (%27.6)
57.13
14 / 16
27.16
17 (56.7)
18 (%60)
12 (%40)
4 (%13.3)
8 (%26.7)
0 (%0)
0.025
0.013
0.137
0.214
0.139
0.534
<0.001
<0.001
<0.001
HF: heart failure, BMI: body mass index, HT: hypertension, HLP: hyperlipidemia, DM: diabetes
mellitus BB: beta blocker, ACEi: angiotensin converting enzyme inhibitors, MRA: miner-
alokortikoid antogonists
Table-2. miRNA expression fold changes
According to
the normal at admission
According to
the normal at discharge
miR- 22
miR- 24
miR- 92b
miR- 320a
miR- 423-5p
- 2.39 f
- 2.07 f
+ 2.33 f
- 1.56 f
- 1.16 f
- 1.23 f
- 1.59 f
+ 3.0 f
- 1.46 f
+ 1.3 f
miRNA (miR): mikroribonükleic acid
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Background and Aim: Percutaneous coronary intervention (PCI) does not often have
optimal results despite restoration of coronary blood ﬂow at myocardial recovery
because of impaired microvascular perfusion. Previous studies have focused on the
starting time and dosage of tiroﬁban. This study aimed to investigate and evaluate with
99mTc-sestamibi scan whether the results of PCI can be changed by maintenance
infusion of the tiroﬁban for 24 or 48 hours in patients presenting with anterior STEMI.
Methods: The study consisted of 84 patients with anterior STEMI who were candi-
dates to undergo primary PCI and whose occlusion were in proximal or mid left
anterior descending artery (LAD), were given 25mg/kg/3 minutes tiroﬁban and
randomized maintenance infusion of 0.15mg/kg/minute for 24 or 48 hours. A resting
99mTc sestamibi scan was performed at post-procedure 5th day before discharge and
the primary efﬁcacy end point was a 5-point scoring system for perfusion defect
severity. Major adverse cardiac events were deﬁned as death from any cause, rein-
farction, and clinically driven target-vessel revascularization within the ﬁrst 6 months.
Results: The baseline characteristics were similar at 24 (n¼42) and 48 hours (n¼42)
infusion groups. There was no signiﬁcant difference at the anticipated symptom onset
to presentation time (3.832.09 h at 24 hour infusion group and 4.102.01 h at 48
hour infusion group, p¼0.380) and door to balloon time (45.7115.91 min. at 24 hour
infusion group and 48.9520.78 min. at 48 hour infusion group, p¼0.542) between
two groups. Except for basal anteroseptal and basal anterior segments, signiﬁcant
differences were obtained from the reduction of 5-point scoring system for perfusion
defect severity in segments and in the summed rest scores (apex 2.900.95,
2.041.43; p<0.05; mid-anterior 1.880.94, 1.281.13; p<0.05; mid-anteroseptal
2.280.83, 1.731.14; p<0.05; apical anterior 2.690.81, 2.001.43; p<0.05;,
apical septal 2.640.87, 1.951.32; p<0.05;, apical lateral 2.500.94, 2.211.27;
p<0.05, basal anterior 0.110.32, 0.330.75; p¼0.09; basal anteroseptal 0.660.72,
0.500.91; p¼0.288, SRS 15.614.60, 11.977.34; p<0.05). No signiﬁcant effect
was observed on major adverse cardiac events at 6 months. The safety proﬁle did not
differ between 24 and 48 hour infusion of tiroﬁban.
Conclusion: The use of tiroﬁban, when administered at a high dose of bolus and
maintained for 48 hours, is safe and signiﬁcantly reduces perfusion defect severity in
patients with anterior STEMI presenting early after symptom onset and undergoing
primary PCI.LS C19
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